Open AccessMANAGEMENT OF DEPRESSION IN TERMINALLY ILL PATIENTS – A CRITICAL REVIEW
Author(s) -
O Balaji,
Veeyak
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i5.17345
Subject(s) - depression (economics) , psychological intervention , medicine , quality of life (healthcare) , cancer , psychiatry , management of depression , life span , broad spectrum , intensive care medicine , alternative medicine , gerontology , nursing , chemistry , pathology , economics , combinatorial chemistry , macroeconomics
Depression is a well-recognized risk factor for shortened life span from cancer. Depression is among the main causes of disability in the world leadingto increased suffering and mortality. As per research surveys over the years, prevalence among cancer patients varies widely from 3% to 38% formajor depression and 1.5-52% for depression spectrum syndromes. The need of the hour is to effectively treat depression in cancer patients so thatthe quality of life can be improved and thereby patient survival. Both psychological and pharmacological interventions and the combination of bothvery much effective in treating depression in cancer patients. A broad range of therapies now exist, and the art of such therapy is the strategic selectionof components from several models to best respond to the needs of the individual patient and his/her family in the specific circumstances, whetherclinical, psychological, spiritual, or social.Keywords: Depression, Tricyclic anti-depressants, Psychotherapy, Adverse effects.